- Pharmaceutical companies
- Novartis
Novartis
Phone: +355 4 223 2444
Fax: +355 4 223 0843
Type | Public (Aktiengesellschaft) |
---|---|
Traded as | |
ISIN | |
Industry | Pharmaceuticals |
Predecessors |
|
Founded |
|
Founders |
|
Headquarters |
|
Area served | Worldwide |
Key people | Vasant Narasimhan (CEO) |
Products | Pharmaceutical drugs, generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses, animal health (list...) |
Revenue | US$51.63 billion (2021) |
Operating income | US$11.69 billion (2021) |
Net income | US$24.02 billion (2021) |
Total assets | US$131.79 billion (2021) |
Total equity | US$67.82 billion (2021) |
Number of employees | 110,000 (2021) |
Website | www.novartis.com |
Novartis is structured to deliver innovative products, exploit global scale, and respond to new opportunities and risks. Our purpose is to reimagine medicine to improve and extend people's lives. We use innovative science and technology to address some of society's most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to reward those who invest their money, time and ideas in our company.
For detailed contact information visit location pages below.
Novartis's locations around the world
Europe
-
Albania
-
Austria
-
Belarus
-
Belgium
-
Bosnia & Herzegovina
-
Bulgaria
-
Croatia
-
Czech Republic
-
Denmark
-
Estonia
-
Finland
-
France
-
Germany
-
Greece
-
Hungary
-
Iceland
-
Ireland
-
Italy
-
Latvia
-
Lithuania
-
Luxembourg
-
Macedonia
-
Malta
-
Montenegro
-
Netherlands
-
Norway
-
Poland
-
Portugal
-
Romania
-
Russia
-
Serbia
-
Slovakia
-
Slovenia
-
Spain
-
Sweden
-
Switzerland
-
Ukraine
-
United Kingdom
North America
Asia
Africa
Oceania
Clinical Trials sponsored by Novartis
-
Novartis PharmaceuticalsNon ancora reclutamentoSclerosi multipla, recidivante-remittente
-
Novartis PharmaceuticalsNon ancora reclutamentoArtrite reumatoide | Lupus eritematoso sistemico | Malattia di Sjögrens
-
Novartis PharmaceuticalsNon ancora reclutamentoLp(a) elevata e malattia cardiovascolare aterosclerotica accertata
-
Novartis PharmaceuticalsReclutamentoForme recidivanti di sclerosi multiplaSpagna
-
Novartis PharmaceuticalsReclutamento
-
Novartis PharmaceuticalsNon ancora reclutamento
-
Novartis PharmaceuticalsReclutamento
-
Novartis PharmaceuticalsNon ancora reclutamento
-
Novartis PharmaceuticalsReclutamentoHR+HER2- Cancro al seno avanzatoFederazione Russa
-
Novartis PharmaceuticalsReclutamentoMalattia coronarica | Emopoiesi clonale a potenziale indeterminato (CHIP)Germania, Canada